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Salvinorin A is a potent hallucinogen, isolated from the ethnomedical plant Salvia
divinorum. Salvinorin A is a selective high efficacy kappa-opioid receptor (KOPr)
agonist, and thus implicates the KOPr system and its endogenous agonist ligands (the
dynorphins) in higher functions, including cognition and perceptual effects. Salvinorin
A is the only selective KOPr ligand to be widely available outside research or
medical settings, and salvinorin A-containing products have undergone frequent non-
medical use. KOPr/dynorphin systems in the brain are known to be powerful counter-
modulatory mechanisms to dopaminergic function, which is important in mood and
reward engendered by natural and chemical reinforcers (including drugs of abuse).
KOPr activation (including by salvinorin A) can thus cause aversion and anhedonia
in preclinical models. Salvinorin A is also a completely new scaffold for medicinal
chemistry approaches, since it is a non-nitrogenous neoclerodane, unlike other known
opioid ligands. Ongoing efforts have the goal of discovering novel semi-synthetic
salvinorin analogs with potential KOPr-mediated pharmacotherapeutic effects (including
partial agonist or biased agonist effects), with a reduced burden of undesirable effects
associated with salvinorin A.
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Salvinorin A
Salvinorin A (derived from the ethnomedical plant Salvia divinorum) is a powerful hallucinogen
in humans, and is a selective, high efficacy agonist at kappa-opioid receptors (KOPr; Roth et al.,
2002; Chavkin et al., 2004). Salvinorin A is unique for several reasons, which include: (a) it is the
first plant-derived ligand with high selectivity for KOPr over other receptors, including mu-opioid
receptor (MOPr) (the target of opioid alkaloids, such as morphine), (b) it is structurally unrelated
to any known opioid receptor ligand, and is a non-nitrogenous diterpene, (c) it is pharmacologically
and mechanistically distinct from other known hallucinogens in humans (e.g., classic serotonergic
hallucinogens, which are primarily 5HT2A agonists), (d) it is the only selective KOPr ligand to
become relatively widely available outside research or medical settings. This is also related to its
diffusion through the internet and other commercial outlets, due to its complex legal status across
jurisdictions.
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The KOPr System and its Endogenous
Agonist Neuropeptides, the Dynorphins
KOPr receptors are members of the opioid receptor 7-
transmembrane domain (7TM) G-protein coupled receptor
(GPCR) superfamily, coupled primarily to Gi=o proteins that
inhibit actions of adenylyl cyclase, and also activate alternate
downstream pathways, including b-arrestin-mediated pathways
and ERK/MAP kinase pathways (Dhawan et al., 1996; Bruchas
and Chavkin, 2010; Zhou et al., 2013a). The endogenous KOPr
agonists are the dynorphin neuropeptides, encoded by gene
PDYN in humans (Chavkin and Goldstein, 1981; Chavkin, 2012).
KOPr and the dynorphins are located in many parts of the
central nervous system (CNS; and also in the peripheral nervous
system). In the CNS, KOPr/dynorphin systems are prominent
in the dorsal and ventral striatum (e.g., caudate-putamen and
Nucleus accumbens, respectively), several cortical areas, and
limbic areas including hippocampus and amygdala, as well as
hypothalamus and spinal cord (Mansour et al., 1988; Spangler
et al., 1993; Unterwald et al., 1994; Simonin et al., 1995; Mathieu-
Kia et al., 2001). Thus, this receptor/ligand system mediates
diverse behavioral functions, including mediation of reward
and aversion, mood, anxiety, stress-responsivity, memory and
higher cognitive functions, as well as neuroendocrine effects
and pain/analgesia. KOPr/dynorphin systems are co-localized
in most major dopaminergic areas in the CNS. KOPr activation,
by exogenous ligands including salvinorin A, or by dynorphins,
tends to result in a decrease in dopaminergic activation in dorsal
and ventral striatum (Di Chiara and Imperato, 1988; Spanagel
et al., 1990; Zhang et al., 2004, 2005; Carlezon et al., 2006; i.e.,
an effect opposite to that of diverse drugs of abuse, including
cocaine, other psychostimulants and MOPr agonists).
Effects of KOPr Activation on Behavioral
and Neurobiological Endpoints
Based on preclinical studies in rodents and non-human primates,
and in human Laboratory studies, activation of KOPr is thought
to result in a variety of robust effects summarized below: (a)
decreases in locomotor activity and arousal, also manifested
as sedative-like behaviors, (b) dysphoria and aversion, (c)
depressant-like behaviors and (d) modulation in the effects of
drugs of abuse (e.g., in conditioned place preference or self-
administration studies). Of interest, in the Laboratory—based
human research studies to date (carried out in experienced
hallucinogen users), salvinorin A did not result in robust
dysphoric or aversive subjective effects (in the presence of other
robust subjective effects, including hallucinations; Johnson et al.,
2011; Addy, 2012; Ranganathan et al., 2012; MacLean et al., 2013).
It is unknown if this is due to experimental context, subject
population characteristics, or to a differential pharmacodynamic
profile of salvinorin A, compared to synthetic KOPr agonists used
in other studies in humans (Pfeiffer et al., 1986; Pande et al.,
1996). For example, it is unknown if repeated prior exposure
to salvinorin A in the recruited subjects resulted in relative
development of neuroadaptations, including tolerance, in KOPr
populations.
Status of the KOPr/dynorphin System
During Stress, or in Addictive States
Notably, endogenous activation of KOPr caused by stress can
result in several of the aforementioned types of behaviors (e.g.,
depressant-like behaviors), primarily by increases in dynorphin
actions, in specific neuroanatomical areas (Zhang et al., 2007;
Reed et al., 2012; Cohen et al., 2014). Stress exposure can also
result in relapse-like behaviors in preclinical models, in part
mediated by endogenous KOPr/dynorphin activation (Beardsley
et al., 2005; Aldrich et al., 2013; Zhou et al., 2013b). Also,
exposure to drugs of abuse (e.g., cocaine, other psychostimulants
or short-acting MOPr agonists, such as morphine) results in
an upregulation in the KOPr/dynorphin system, as measured
either by KOPr autoradiography, by signaling assays, or by PDYN
mRNA (Daunais et al., 1993; Spangler et al., 1993; Unterwald
et al., 1994; Wang et al., 1999; Adams et al., 2003; Whitfield et al.,
2015). It has been thus hypothesized that several neuropsychiatric
conditions including stress-induced depressant or anxiety-like
effects, as well as escalation of drug intake, and relapse-like
behaviors are mediated in part by KOPr/dynorphin upregulation
(Spangler et al., 1993; Nestler and Carlezon, 2006; Bruchas et al.,
2010; Chavkin, 2011; Butelman et al., 2012b).
Given the diverse and robust effects of KOPr activation in these
behavioral and neurobiological endpoints, a considerable amount
of recent work (mostly preclinical), has focused on acute and
chronic effects of salvinorin A exposure.
In vivo Effects of Salvinorin A
Salvinorin A causes overt sedative-like and locomotor-decreasing
effects in rodent and non-human primate models (including
unresponsiveness to environmental stimuli; Fantegrossi et al.,
2005; Zhang et al., 2005; Butelman et al., 2009). These effects
are qualitatively similar to those of synthetic KOPr agonists, and
are sensitive to KOPr antagonism (Fantegrossi et al., 2005; Zhang
et al., 2005; Butelman et al., 2009). Hallucinogenic effects per se are
difficult to model in a valid manner in non-human models, since
they depend on interoceptive and subjective states that are not
easily discernible by behavioral observation in non-verbal species.
Drug Discrimination
Data from non-human primate and rodent models show
that discriminative effects salvinorin A (potentially modeling
interoceptive effects) are mediated by agonist effects at KOPr,
and not by 5HT2A receptors, site of action of most classic
hallucinogens (such as LSD and psilocybin; Roth et al., 2002;
Butelman et al., 2004b, 2010; Li et al., 2008; Baker et al., 2009;
Killinger et al., 2010). Recent studies in humans also show that
naltrexone (50 mg, p.o.) blocked the effects of salvinorin A in
humans (Valle et al., 2014). This is consistent with blockade of
KOPr agonist effects of salvinorin A, since sufficient doses of
naltrexone can robustly block the effects of diverse KOPr ligands
in human and non-human primates (these naltrexone doses are
usually larger than doses minimally required to block MOPr
mediated effects; Ko et al., 1998; Butelman et al., 2004a; Walsh
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et al., 2008). Overall these data implicate the KOPr/dynorphin
system as a mechanism mediating several higher functions,
including mood, sedation and arousal, as well as depressant-like
effects, perception and higher cognitive functions.
Neuroendocrine Effects
KOPr agonists have specific neuroendocrine effects, including
prolactin release and also stimulation of HPA axis hormones,
ACTH and cortisol (or corticosterone in rodents; Adamson et al.,
1991; Ur et al., 1997; Kreek et al., 1999; Pascoe et al., 2008). These
effects are thought to be primarily mediated by KOPr at different
hypothalamic sites, including arcuate and paraventricular nuclei,
although this has not been unequivocally confirmed.
Prolactin has been used as a simple quantitative biomarker of
KOPr agonist effects, and it can be used to discern onset, potency
(e.g., ED50) and apparent efficacy ofKOPr ligands (Butelman et al.,
1999; Kreek et al., 1999; Bart et al., 2005; Chang et al., 2011;
other compounds, including MOPr agonists, also cause prolactin
release). Salvinorin A was found to be a potent efficacious,
and rapid-onset KOPr agonist in this biomarker in non-human
primates with high KOPr homology to humans (Butelman et al.,
2007). Recent work in humans also reported similar effects (see
below; Ranganathan et al., 2012).
Salvinorin A Effects in Preclinical Assays
for Neuropsychiatric Diseases (e.g., Mood,
Anxiety, and Addictions)
Similarly to synthetic KOPr agonists and to endogenous KOPr
ligands (dynorphins), salvinorin A causes a dose-dependent
decrease in dopamine dialysates in dorsal and ventral striatum
of rodents (Zhang et al., 2005; Carlezon et al., 2006); these
effects occur at doses similar to those that cause behavioral
effects such as place aversion, depressant-like effects, and
locomotor decreases. Neurobiological studies suggest that one
possible mechanism of the decreases in dopamine levels may
be a salvinorin A-induced potentiation of dopamine re-uptake
transporter (DAT) function, and this may be secondary to the
formation of KOPr/DAT heterodimers (Kivell et al., 2014). Acute
and chronic effects of salvinorin A on dopaminergic systems
may also differ (Gehrke et al., 2008), of possible relevance to
repeated users of salvinorin A-containing products. Paradoxically,
some studies have reported that relatively smaller salvinorin A
doses cause a detectable enhancement of dopamine dialysate
levels (Braida et al., 2008; Serra et al., 2015). The differential
mechanisms involved in this latter effect have not been fully
elucidated.
Salvinorin A, similarly to synthetic KOPr agonists, results
in dose-dependent conditioned aversion (e.g., in contextual
conditioning assays; Zhang et al., 2005). Also, salvinorin A can
act as a “punisher” to self-administration of cocaine or a short-
acting MOPr agonist in primates (when given contingently;
Whitfield et al., 2015). These studies would appear to be
discrepant with the relatively wide experimentation observedwith
salvinorin A-containing products in humans. However, it should
be noted that classic serotonergic hallucinogens self-administered
by humans do not produce stable or robust reinforcing effects in
preclinical studies (Fantegrossi et al., 2004). Furthermore, self-
administration of hallucinogens in humans tends to follow a
more episodic nature than that of other drugs of abuse, including
cocaine or MOP-r agonists, and may occur in specific subsets
of the human population that find hallucinogens rewarding or
attractive.
Salvinorin A also results in anhedonia in ICSS assays and
depressant-like effects in the forced swim test, similarly to
synthetic KOPr agonists (Carlezon et al., 2006; Negus et al.,
2012). KOPr antagonists, by contrast, can block these salvinorin
A-induced effects, and alone also produce anti-depressant like-
effects, and anxiolytic-like effects (Carlezon et al., 2006; Negus
et al., 2012; Reed et al., 2012; Rorick-Kehn et al., 2014). These
findings lead to the postulation that prolonged high efficacy
signaling through KOPr results in behavioral and neurobiological
effects associated with human neuropsychiatric conditions,
especially depression-like and anxiety-like states, and specific
addictions. Conversely, novel compounds with limited efficacy
at KOPr (such as antagonists or appropriate partial agonists) or
compounds with “biased” KOPr signaling, could potentially have
pharmacotherapeutic effects in mood, anxiety or addictive states
(see below; Neumeyer et al., 2001; Butelman et al., 2012b; Tejeda
et al., 2012; Bidlack, 2014; Simonson et al., 2014; Lovell et al., 2015;
Whitfield et al., 2015).
Studies of Salvinorin A and Salvia
divinorum in Humans
There have been initial descriptive and ethnographic reports of
Salvia divinorum or salvinorin A exposure (Valdes et al., 1983;
Siebert, 1994). More recently several controlled laboratory-based
studies have characterized the in vivo effects of salvinorin A or
Salvia divinorum in humans (Johnson et al., 2011; Mendelson
et al., 2011; Addy, 2012; Ranganathan et al., 2012; MacLean et al.,
2013). There have also been several questionnaire-based studies
and clinical case studies of the effects of salvinorin A-containing
preparations in humans (Singh, 2007; Lange et al., 2008; Przekop
and Lee, 2009; Baggott et al., 2010; Wu et al., 2011; Perron et al.,
2012).
Carefully controlled studies in humans, initially experienced
hallucinogen or Salvia divinorum users, characterized the effects
of salvinorin A smoking (0.75–21 mg/kg). Salvinorin A’s effects
were of extremely rapid onset, peaked by 2 min after inhalation,
and declined by 30 min (Johnson et al., 2011; MacLean et al.,
2013). Under these carefully monitored conditions, volunteers
reported robust hallucinogenic-like effects, depersonalization
and derealization, but no robust dysphoria or aversion (Johnson
et al., 2011). It is unknown if effects in a different population
(i.e., non-hallucinogen users) would show a more robust
dysphoria/aversion signal, consistent with effects observed in
preclinical rodent models (Zhang et al., 2005; Carlezon et al.,
2006), or dysphoric effects reported with synthetic KOPr agonists
in humans (Kumor et al., 1986; Pfeiffer et al., 1986; Pande et al.,
1996;Walsh et al., 2001). A separate study with smoked salvinorin
A (in volunteers with previous self-exposure to Salvia divinorum)
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reported dose-dependent and reversible psychotomimetic effects,
dissociation, and neuroendocrine effects (increases in serum
cortisol and prolactin; Ranganathan et al., 2012). A further
study examined the effects of Salvia divinorum smoking,
and characterized subjective experiences including cognitive
alterations, which were also robust and time-dependent (Addy,
2012).
Overall, the above controlled studies in humans confirm the
basic pharmacology of salvinorin A in humans as a potent and
fast-acting high efficacy KOPr agonist, as previously determined
in rodent and non-human primate models.
Salvinorin A as a Novel Scaffold for KOPr
Medicinal Chemistry and Pharmacotherapy
of Neuropsychiatric Disorders
As mentioned above, salvinorin a is a non-nitrogenous diterpene,
and provides a new scaffold for development of newKOPr ligands,
by semi-synthetic methods (Beguin et al., 2012; Prisinzano, 2013;
White et al., 2015). Salvinorin A per se has several effects that
complicate its use as a pharmacotherapeutic tool in humans,
including dissociative and hallucinogenic effects, thought to
be due to high efficacy KOPr agonism (Johnson et al., 2011;
Ranganathan et al., 2012; MacLean et al., 2013). Salvinorin A also
has extremely rapid onset and relatively short duration of action
in humans and non-human primates, possiblymediated in part by
the p-glycoprotein blood-brain barrier efflux transporter (Hooker
et al., 2008; Butelman et al., 2009, 2012a; Johnson et al., 2011), and
such rapid on/off effects further complicate its study in humans.
Medicinal chemistry efforts focusing on semi-synthetic
salvinorin A analogs have resulted in some compounds with a
differential in vivo profile compared to the parent neoclerodane
(salvinorin A). These differential profiles may be due to a more
gradual onset/offset (Wang et al., 2008), or to pharmacodynamic
factors, including KOPr partial agonism, or differential signaling
through downstream pathways (“biased agonism”; Zhou et al.,
2013a). For example, some analogs, including 16-Br-salvinorin
A and Mesyl-salvinorin B were able to decrease reinstatement of
cocaine self-administration in rats, with a decreased burden of
sedative-like effects, as caused by salvinorin A or by reference
KOPr agonists (Riley et al., 2014; Simonson et al., 2014).
Salvinorin A and some common reference KOPr agonists (such
as U69,593 and (-)-U50,488) have been classified as “unbiased”
KOPr ligands, that is, they activate the adenylyl cyclase and b-
arrestin pathways with approximately equal potency and efficacy
(White et al., 2014). Of interest, 22-thiocyanatosalvinorin A (RB
64), a “biased” ligand (with greater potency at the adenylyl cyclase
pathway compared to the b-arrestin signaling pathway), was able
to produce antinociception in mice, with a reduced tendency to
cause some undesirable effects such as locomotor incoordination
in the rotorod assay (White et al., 2014, 2015). These efforts
point the possibility of novel salvinorin-based neoclerodanes with
therapeutic-like effects in preclinical models of neuropsychiatric
states (including addictions and pain), with a reduced burden of
“on-target” undesirable effects known to be caused by salvinorin
A, or by classic KOPr agonists.
Summary and Main Points of
Consideration for Future Research
(a) Salvinorin A is a unique and potent plant-derived
hallucinogen, and is a short-acting high efficacy KOPr
agonist.
(b) KOPr (encoded by gene OPRK1) are present in several
areas of the CNS and periphery, and are activated by their
endogenous agonist neuropeptide ligands, the dynorphins
(encoded by gene PDYN). KOPr/dynorphin systems are one
of the major counter-modulatory systems to dopaminergic
activation, in striatal pathways known to mediate motor
activity, arousal and responses to natural and drug reinforcers.
KOPr/dynorphin systems are also present in areas involved in
mood, anxiety and stress processing (including amygdala and
hypothalamus).
(c) Exposure to stress or to drugs of abuse (e.g., cocaine
and other psychostimulants) results in an upregulation in
KOPr/dynorphin activity, and this may underlie, in part,
neurobiological and behavioral effects observed in these
conditions.
(d) KOPr agonists including salvinorin A have characteristic
effects in preclinical models, and cause anhedonia,
depressant-like and sedative-like behaviors. These behaviors
may in part be due to the KOPr-agonist induced counter-
modulation of dopaminergic brain systems (mentioned
above).
(e) The prominent salvinorin A-induced hallucinogenic effects
implicate theKOPr/dynorphin system in higher cognitive and
perceptual functions, in health and disease.
(f) Salvinorin A is a novel scaffold for medicinal chemistry
approaches, with the goal of generating novel compounds
with pharmacotherapeutic potential, in neuropsychiatric
diseases, including specific addictions.
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